£1.7M
The funding will support proof-of-principle work for detecting Pseudomonas aeruginosa infections in patients.
Owlstone Medical
Owlstone Medical provides breath biopsy technology for early disease detection and precision medicine.
£65.7MTotal raised
Owlstone Medical develops breath-based diagnostics using its proprietary Breath Biopsy platform for applications in early disease detection and precision medicine.
Categories
Founders
Billy Boyle
co-founder and CEO
Billy serves as co-founder and chief executive officer of Owlstone Medical, having previously co-founded Owlstone. He also brings academic research experience from the University of Cambridge.
LinkedInInvestors
- £1.7M
- £22.0M
- £42.0M
Funding history
£22.0M
Ventura Capital led the Series E round, with participation from Aviva Ventures, Horizons Ventures, and the Gates Foundation, to advance clinical trials and commercialise breath tests.
£42.0M
The oversubscribed financing round will support the commercialisation of proprietary breath biopsy tests.